Although the introduction of tumor treating fields (TTFields) to the therapeutic scheme and, most recently, the results of the CeTeG/NOA-09 trial, which proved a benefit of combined TMZ and lomustine chemotherapy for O6-methylguanine-DNA methyltransferase (MGMT)-methylated patients, promise hope for improving perspectives, identifying new therapeutic targets and approaches is still a major task in GBM research [9,10,11,12,13]. This evidence concerns the gene MGMT and glioblastoma.